1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. Summary
    NTRA   US6323071042

NATERA, INC.

(NTRA)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
38.79 USD   +5.04%
06/29Natera Says Study Validates Performance of Its Prospera Transplant Rejection Test
MT
06/29Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
PR
06/14TRANSCRIPT : Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
37.72(c) 36.87(c) 35.44(c) 36.93(c) 38.79(c) Last
872 238 1 305 973 1 039 602 743 924 819 840 Volume
-5.01% -2.25% -3.88% +4.20% +5.04% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 805 M - -
Net income 2022 -573 M - -
Net cash position 2022 60,5 M - -
P/E ratio 2022 -6,58x
Yield 2022 -
Sales 2023 1 002 M - -
Net income 2023 -513 M - -
Net Debt 2023 121 M - -
P/E ratio 2023 -7,66x
Yield 2023 -
Capitalization 3 736 M 3 736 M -
EV / Sales 2022 4,56x
EV / Sales 2023 3,85x
Nbr of Employees 2 670
Free-Float 96,0%
More Financials
Company
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free deoxyribonucleic acid (DNA) or (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single... 
More about the company
Ratings of Natera, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about NATERA, INC.
06/29Natera Says Study Validates Performance of Its Prospera Transplant Rejection Test
MT
06/29Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Re..
PR
06/14TRANSCRIPT : Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conferen..
CI
06/09NATERA : 2022 Proxy Statement
PU
06/01NATERA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/31Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at th..
PR
05/26NATERA, INC. COMPANY NEWS : Berger Montague Investigates Securities Fraud Allegations Agai..
PR
05/24Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
PR
05/24Natera, Inc. Announces Executive Changes
CI
05/16Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additi..
PR
05/16Piper Sandler Adjusts Natera's Price Target to $60 From $75, Reiterates Overweight Rati..
MT
05/09JPMorgan Adjusts Price Target for Natera to $80 From $150, Maintains Overweight Rating
MT
05/09Morgan Stanley Lowers Natera's Price Target to $70 From $110, Maintains Overweight Rati..
MT
05/06NATERA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/05NATERA : Q1 Earnings Snapshot
AQ
More news
News in other languages on NATERA, INC.
06/29Natera affirme que l'étude valide la performance de son test de rejet de greffe Prosper..
05/24Natera, Inc. annonce des changements de direction
05/05La perte de Natera au premier trimestre se creuse alors que le chiffre d'affaires augme..
05/05Earnings Flash (NTRA) NATERA affiche un chiffre d'affaires de 194,1 millions de dollars..
05/05Natera, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 38,79 $
Average target price 84,73 $
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Stephen Chapman Chief Commercial Officer
Michael Burkes Brophy VP-Corporate Development & Investor Relations
Matthew Rabinowitz President, Chief Executive Officer & Director
Eric A. Evans Chief Scientific Officer
Rishi Kacker Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
NATERA, INC.-58.46%3 736
BIOMÉRIEUX-21.10%11 937
DIASORIN S.P.A.-21.11%7 342
10X GENOMICS, INC.-66.44%5 667
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.3.27%5 322
LANTHEUS HOLDINGS, INC.124.06%4 443